Valens Semiconductor reported a strong Q3 2025, exceeding revenue guidance with $17.3 million driven by robust demand in the ProEV market, marking the sixth consecutive quarter of growth.

• Revenue of $17.3 million surpassed guidance of $15.1–$15.6 million, with expectations for Q4 2025 revenue to range between $18.2–$18.9 million.
• GAAP gross margin reached 63%, outperforming projections, while adjusted EBITDA loss was $4.3 million.
• Significant product traction noted for VF3000 and VA7000 chipsets, positioning Valens for strong growth in ProEV and medical sectors.
• Successful launch of V7000-based disposable endoscopies highlights innovation in medical technology, catering to emerging trends in minimally invasive procedures.
• Leadership transition to Johann Stalinger as CEO effective tomorrow, signifying a strategic shift in executive management stability.